PATENT CLAIM ANALYSIS

Application Number: 16001711
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["424", "464000"]

Abstract:
The present disclosure provides a safe method for anesthesia or the treatment of pain by safely administering an amount of active agent to a patient while reducing the incidence or severity of suppressed respiration. The present disclosure provides a pharmaceutical composition comprising a therapeutic agent and a chemoreceptor respiratory stimulant. In one aspect, the compositions oppose effects of respiratory suppressants by combining a chemoreceptor respiratory stimulant with an opioid receptor agonist or other respiratory-depressing drug. The combination of the two chemical agents, that is, the therapeutic agent and the respiratory stimulant, may be herein described as the “drugs.” The present compositions may be used to treat acute and chronic pain, sleep apnea, and other conditions, leaving only non-lethal side effects.

Claim (Index 4):
The method of  claim 1 , wherein the doxapram is 1-ethyl-4-[2-(4-morpholinyl)ethyl]-3,3-diphenyl-2-pyrrolidinone monohydrochloride, monohydrate.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 94.0
- Lexical Diversity: 1.68354
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15214421', '12552596', '14950707', '15335145', '14659472']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7267743879411753
- 35 USC 102 Novelty (BERT): 0.5568160267531952
- Combined Prediction Score: 0.7097785518223774
- Mean Citation Score: 251.110712
- Max Citation Score: 412.08447
- Similarity Product: 409.8218785710649

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test